Tumours of the upper aerodigestive tract (UADT) have long been considered unresponsive to cytotoxic chemotherapy (Greenberg, 1984) . For some time, methotrexate and bleomycin were essentially the only effective chemotherapeutic agents (Bertino et al., 1975; Carter, 1977) . These drugs were often used after local treatment (surgery and/or radiotherapy) on disease recurrence or metastasis, but results were generally disappointing. Objective response rates were significantly improved in the 1970s by the introduction of cis-platin, used both alone and in combination with other drugs (Jacobs et al., 1978) . The highest response rates were produced by induction chemotherapy given before any local treatment (Glick et al., 1980) .
Following the work of Al-Sarraf et al. (1979) and Kish et al. (1982) , we have treated UADT tumours with an induction combination of cis-platinum (CDDP) and 5-fluorouracil (5-FU) since 1983. Our promising preliminary results (Thyss et al., 1985) have now been confirmed by this more complete investigation of 108 cases. CDDP 100mgm-2 on day 1 followed by 5-FU 1000mgm-2 from day 2 to day 6. The protocol called for three courses per patient. The interval between cycles was 10 days for the first 63 patients (Dl=D17=D33); the interval for subsequent patients was lengthened to 15 days (Dl = D22 = D43). 
Patients
A total of 108 patients (94 men, 14 women) were entered in the study; mean age was 61 years (range 36-82). Table I lists patient data by TNM criteria. Most patients were T3-T4 (n = 84, 78%). The distribution between NO (54 patients) and N2, 2, 3 (54 patients) was identical. The distribution by UICC criteria was as follows: 18 stage II (17%); 61 stage III (56%); 29 stage IV (27%). No patient had distant metastasis. The sites of primary tumours were as follows: 20 oral cavity (18%), 50 oropharynx (40%), 30 larynx or hypopharynx (28%), 4 facial sinuses (4%), 4 rhinopharynx (4%).
Protocol feasibility
The treatment protocol proved feasible because the doses actually administered were greater than or equal to 90% of the planned dose for 88 patients (82%). Moreover, 90 patients (83.5%) received all three chemotherapy courses, and the interval between cycles was as protocol in most cases. The Results for metastatic lymph nodes (Table IV) As is often the case, the quality of clinical response was not as good for metastatic lymph nodes as for Most of the patients experienced the nausea and vomiting commonly observed with treatments including cis-platinum. Venous damage (including pigmentation) attributable to 5-FU was also common, and was only partially prevented by keeping the infused limb in the dark. Electrolyte disorders such as hypokaliemia and hypomagnesemia were common; systematic monitoring is therefore warranted for detection and correction. Disturbances in appetite, including severe anorexia, were frequent during chemotherapy. Haematological toxicity was evaluable for 307 cycles using WHO criteria: there were 262 grade 0 cycles (85.5%), 29 grade I or II (9.5%), and 16 grade III or IV (5%). Evaluation of gut toxicity (mucositis and/or diarrhoea) with WHO criteria gave the following results: 245 grade 0 cycles (80%), 50 grade I or 11 (16%), and 12 grade III or IV (4%). Most gut toxicity consisted of oral mucositis. The frequency of mucositis was reduced when the 10 day interval between cycles was increased to 15 days.
Other toxic manifestations included a transient rise in plasma creatinine, which regressed after several days for 2 patients, and balanitis for 2 other patients. Eight patients had particularly severe asthenia (6 of them were aged >70 years). Four deaths were attributable to the chemotherapy regimen, but all patients (aged 67, 70, 71 and 74 years) had significant medical complications: decompensated alcoholic cirrhosis (1 case), myocardial infarction 5 years earlier (1 case), severe arteriosclerosis of the lower limbs requiring amputation (2 cases).
Finally, in contrast to certain recent reports (Slotman et al., 1984) (over 60%) and distant metastatis (20%-30%) (Probert et al., 1978) . While results with initial trials using methotrexate were controversial (Ervin et al., 1980; Fazekas et al., 1980) , various multidrug regimens proved more effective, and frequent complete responses were obtained. CDDP combined with bleomycin (BLM) (Hong et al., 1979) and/or vinca alkaloids and/or methotrexate (MTX) are among the most effective associations, with data indicating objective responses in 48%-100% of patients so treated (Brown et al., 1980; Randolph et al., 1978) . In an earlier study covering 85 patients, we obtained objective lesion regression in 56.6% of patients after systemic administration of 2 courses of an induction chemotherapy regimen including vincristine (VCR), BLM, MTX and CDDP; this rate rose to 76.5% for patients who received the same regimen by an intra-arterial route (Demard et al., 1985) .
As first demonstrated in experimental animal models (Schabel et al., 1979) , associating 5-FU with CDDP considerably potentiates the action of both drugs. Since 1980, several studies have been performed on UADT tumours using different doses, modes of administration, and number of courses. Rooney et al. (1985) achieved best results with 3 cycles of a regimen including CDDP 100mgm-2 day 1 followed by a continuous 120h infusion of 5-FU 1000mg 24 h-1. While their overall response rates were similar for 2 and 3 courses (respectively 88% and 93%), the rate of complete regressions was clearly in favour of 3 courses (54% versus only 19% for 2 courses; P = 0.00,4). Lacau et al. (1985) , using a CDDP, 5-FU, BLM combination, observed a significant increase in the percentage of complete responses between the 2nd and 3rd courses.
Our results are comparable; our overall response rate of 86.5% included 35% complete responses. Analysis of results confirmed that the chemotherapy regimen used was more effective on primary tumours than on metastatic lymph nodes: 85% response rate for primary tumours, including 47% complete responses (the quality of response decreased as the tumour size increased) versus only 66% for lymph nodes (33% complete responses).
The anatomical site of lesions also a fected results: more complete regres'ions were obtained for lesions of the oropharynx and hypopharynx than for oral cavity tumours (53% versus 31.5%).
The difference between clinical and histological evaluation of tumour response warrants mention. While it is not surprising that minimal histological lesions were detected in certain patients clinically graded CR, the fact that 5 of the twenty-one PR patients no longer had any histological lesions is more remarkable. This is probably due to the fact that persistence of minimal anomalies at the initial tumour site creates doubt as to the complete nature of clinical response. On physical examination, CR and PR patients were actually very similar when compared with respect to their histological status.
Administration of 3 courses of our multidrug regimen proved feasible, despite the unquestionable problem of toxicity (especially gut, mucosal and venous toxicity), which can be reduced to a minimum with adequate hydration, correction of electrolyte disorders, and appropriate patient renutrition. Valuable information allowing prediction of toxic manifestations can also be obtained by pharmacokinetic studies (Thyss et al., 1985a, b) .
The most important question at present is evaluation of the effect of such chemotherapy on prognosis, in other words on the disease-free interval and on survival. At short term, induction chemotherapy improved the local control rate: 80/101 evaluable patients in our series were controlled after subsequently undergoing surgery alone (19 patients), radiotherapy alone (69 patients), or surgery followed by irradiation (13 patients). These figures reflect a marked reduction in the use of certain major surgical procedures following response to induction chemotherapy. When a CR is obtained for a patient initially scheduled to undergo radical mutilating surgery (transmaxillary bucco-pharyngectomy, subtotal glossectomy, laryngectomy or total pharyngecolaryngectomy), the treatment strategy may be changed in favour of irradiation. This is true for increasing numbers of patients. This advantage insofar as it concerns patient comfort and functional results is decisive in our opinion, and sufficient to justify use of this induction chemotherapy regimen even though it has not yet been proved that it improves the disease-free interval or survival.
Several publications have reported an improvement in both the disease-free interval and survival for patients administered induction chemotherapy, but comparisons were made with historical controls (Ervin et al., 1984) . With a VCR/BLM/MTX/CDDP combination, we demonstrated that the duration of survival was significantly longer for patients who achieved a CR or PR (Demard et al., 1983) . CDDP plus 5-FU has given results which confirm this benefit (Ensley et al., 1984) . Moreover, certain studies have shown the CDDP/5-FU regimen to be superior to CDDP/VCR/BLM; they have also revealed the benefits of 3 courses rather than only 2 courses for survival (Rooney et al., 1985) .
Although our follow-up period is still too short for any definitive conclusions to be drawn, there is a statistically significant difference in survival at 18 months in favour of patients who achieved a CR as opposed to nonresponders (Figure 1 ; P<0.001, log rank test). Recent randomized trials, and particularly that of the EORTC Head and Neck Group (Demard et al., to be published), have not shown any differences between these two groups of patients, but none of them has used this CDDP/ 5-FU combination, which gives much better results than other protocols. New controlled trials are thus justified and warrant immediate attention.
